Potential applications of catestatin in cardiovascular diseases

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Blaschko H, Comline RS, Schneider FH, Silver M, Smith AD. Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature 215(5096), 58–59 (1967).
  Medline CASGoogle Scholar
• 2 Schneider FH, Smith AD, Winkler H. Secretion from the adrenal medulla: biochemical evidence for exocytosis. Br. J. Pharmacol. Chemother. 31(1), 94–104 (1967).
  Medline CASGoogle Scholar
• 3 Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ, Barchas JD. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 324(6096), 476–478 (1986).
  Medline CASGoogle Scholar
• 4 Schmid GM, Meda P, Caille D et al. Inhibition of insulin secretion by betagranin, an N-terminal chromogranin A fragment. J. Biol. Chem. 282(17), 12717–12724 (2007).
  Medline CASGoogle Scholar
• 5 Aardal S, Helle KB. The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul. Pept. 41(1), 9–18 (1992).
  Medline CASGoogle Scholar
• 6 Fasciotto BH, Trauss CA, Greeley GH, Cohn DV. Parastatin (porcine chromogranin A347–419), a novel chromogranin A-derived peptide, inhibits parathyroid cell secretion. Endocrinology 133(2), 461–466 (1993).
  Medline CASGoogle Scholar
• 7 Jean PS, Marie FB, Dominique A. Secretion from chromaffin cells is controlled by chromogranin A-derived peptides. Proc. Natl Acad. Sci USA 85, 1712–1716 (1988). • This was the first paper that predicted the exitence of CST.
  MedlineGoogle Scholar
• 8 Mahata SK, O'Connor DT, Mahata M et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist. J. Clin. Invest. 100(6), 1623–1633 (1997). • This is the first paper that identified CST and its basic function to inhibit catecholamine release.
  Medline CASGoogle Scholar
• 9 Gaede AH, Pilowsky PM. Catestatin in rat RVLM is sympathoexcitatory, increases barosensitivity, and attenuates chemosensitivity and the somatosympathetic reflex. Am. J. Physiol. Regul. Integr. Comp. Physiol. 299(6), 6 (2010).
  Google Scholar
• 10 Bandyopadhyay GK, Vu CU, Gentile S et al. Catestatin (chromogranin A(352–372)) and novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling. J. Biol. Chem. 287(27), 23141–23151 (2012).
  Medline CASGoogle Scholar
• 11 Aung G, Niyonsaba F, Ushio H et al. A neuroendocrine antimicrobial peptide, catestatin, stimulates interleukin-8 production from human keratinocytes via activation of mitogen-activated protein kinases. J. Dermatol. Sci. 61(2), 142–144 (2010).
  MedlineGoogle Scholar
• 12 Akaddar A, Doderer-Lang C, Marzahn MR et al. Catestatin, an endogenous chromogranin A-derived peptide, inhibits in vitro growth of Plasmodium falciparum. Cell. Mol. Life Sci. 67(6), 1005–1015 (2010).
  Medline CASGoogle Scholar
• 13 Radek KA, Lopez-Garcia B, Hupe M et al. The neuroendocrine peptide catestatin is a cutaneous antimicrobial and induced in the skin after injury. J. Invest. Dermatol. 128(6), 1525–1534 (2008).
  Medline CASGoogle Scholar
• 14 Zhang D, Shooshtarizadeh P, Laventie BJ et al. Two chromogranin a-derived peptides induce calcium entry in human neutrophils by calmodulin-regulated calcium independent phospholipase A2. PLoS ONE 4(2), 19 (2009).
  Google Scholar
• 15 Egger M, Beer AG, Theurl M et al. Monocyte migration: a novel effect and signaling pathways of catestatin. Eur. J. Pharmacol. 598(1–3), 104–111 (2008).
  Medline CASGoogle Scholar
• 16 Imbrogno S, Garofalo F, Cerra MC, Mahata SK, Tota B. The catecholamine release-inhibitory peptide catestatin (chromogranin A344–363) modulates myocardial function in fish. J. Exp. Biol. 213(Pt 21), 3636–3643 (2010).
  Medline CASGoogle Scholar
• 17 Halova I, Draberova L, Draber P. Mast cell chemotaxis – chemoattractants and signaling pathways. Front. Immunol. 3, 119 (2012).
  MedlineGoogle Scholar
• 18 O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J. Hypertens. 20(7), 1335–1345 (2002).
  MedlineGoogle Scholar
• 19 Meng L, Ye XJ, Ding WH et al. Plasma catecholamine release-inhibitory peptide catestatin in patients with essential hypertension. J. Cardiovasc. Med. 12(9), 643–647 (2011).
  Google Scholar
• 20 Salem RM, Cadman PE, Chen Y et al. Chromogranin A polymorphisms are associated with hypertensive renal disease. J. Am. Soc. Nephrol. 19(3), 600–614 (2008).
  Medline CASGoogle Scholar
• 21 Zhu D, Wang F, Yu H, Mi L, Gao W. Catestatin is useful in detecting patients with stage B heart failure. Biomarkers 16(8), 691–697 (2011).
  Medline CASGoogle Scholar
• 22 Liu L, Ding W, Li R et al. Plasma levels and diagnostic value of catestatin in patients with heart failure. Peptides 46, 20–25 (2013).
  Medline CASGoogle Scholar
• 23 Wang X, Xu S, Liang Y et al. Dramatic changes in catestatin are associated with hemodynamics in acute myocardial infarction. Biomarkers 16(4), 372–377 (2011).
  Medline CASGoogle Scholar
• 24 Preece NE, Nguyen M, Mahata M et al. Conformational preferences and activities of peptides from the catecholamine release-inhibitory (catestatin) region of chromogranin A. Regul. Pept. 118(1–2), 75–87 (2004).
  Medline CASGoogle Scholar
• 25 Biswas N, Gayen J, Mahata M, Su Y, Mahata SK, O'Connor DT. Novel peptide isomer strategy for stable inhibition of catecholamine release: application to hypertension. Hypertension 60(6), 1552–1559 (2012).
  Medline CASGoogle Scholar
• 26 Tsigelny IF, Kouznetsova VL, Biswas N, Mahata SK, O'Connor DT. Development of a pharmacophore model for the catecholamine release-inhibitory peptide catestatin: virtual screening and functional testing identify novel small molecule therapeutics of hypertension. Bioorg. Med. Chem. 21(18), 5855–5869 (2013).
  Medline CASGoogle Scholar
• 27 Taylor CV, Taupenot L, Mahata SK et al. Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A. Determination of proteolytic cleavage sites in hormone storage granules. J. Biol. Chem. 275(30), 22905–22915 (2000).
  Medline CASGoogle Scholar
• 28 Tsigelny I. Mechanism of action of chromogranin A on catecholamine release: molecular modeling of the catestatin region reveals a β-strand/loop/β-strand structure secured by hydrophobic interactions and predictive of activity. Regul. Pept. 77, 43–53 (1998).
  Medline CASGoogle Scholar
• 29 Biswas N, Curello E, O'Connor DT, Mahata SK. Chromogranin/secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga(364–384)). Cell Tissue Res. 342(3), 353–361 (2010).
  Medline CASGoogle Scholar
• 30 Prommegger R, Ensinger C, Adlassnig C et al. Catestatin–a novel neuropeptide in carcinoid tumors of the appendix. Anticancer Res. 24(1), 311–316 (2004).
  Medline CASGoogle Scholar
• 31 Bitsche M, Mahata SK, Marksteiner J, Schrott-Fischer A. Distribution of catestatin-like immunoreactivity in the human auditory system. Hearing Res. 184(1–2), 16–26 (2003).
  Medline CASGoogle Scholar
• 32 Briolat J, Wu SD, Mahata SK et al. New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A. Cell. Mol. Life Sci. 62(3), 377–385 (2005).
  Medline CASGoogle Scholar
• 33 Mahata SK, Mahata M, Wen G et al. The catecholamine release-inhibitory “catestatin” fragment of chromogranin a: naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses. Mol. Pharmacol. 66(5), 1180–1191 (2004).
  Medline CASGoogle Scholar
• 34 Mahapatra NR, Mahata M, Mahata SK, O'Connor DT. The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters. J. Hypertens. 24(5), 895–904 (2006).
  Medline CASGoogle Scholar
• 35 Mahata SK, Mahata M, Parmer RJ, O'Connor DT. Desensitization of catecholamine release. The novel catecholamine release-inhibitory peptide catestatin (chromogranin a344–364) acts at the receptor to prevent nicotinic cholinergic tolerance. J. Biol. Chem. 274(5), 2920–2928 (1999).
  Medline CASGoogle Scholar
• 36 Taupenot L, Mahata SK, Mahata M, Parmer RJ, O'Connor DT. Interaction of the catecholamine release-inhibitory peptide catestatin (human chromogranin A(352–372)) with the chromaffin cell surface and Torpedo electroplax: implications for nicotinic cholinergic antagonism. Regul. Pept. 95(1–3), 9–17 (2000). • This is an important evidence that CST binds to nAchR receptor and inhibits catecholamine release.
  Medline CASGoogle Scholar
• 37 Mahata SK, Mahapatra NR, Mahata M et al. Catecholamine secretory vesicle stimulus-transcription coupling in vivo. Demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin. J. Biol. Chem. 278(34), 32058–32067 (2003).
  Medline CASGoogle Scholar
• 38 Sahu BS, Obbineni JM et al. Molecular interactions of the physiological anti-hypertensive peptide catestatin with the neuronal nicotinic acetylcholine receptor. J. Cell Sci. 125(2787), 2323–2337 (2012).
  Medline CASGoogle Scholar
• 39 Kennedy BP, Mahata SK, O'Connor DT, Ziegler MG. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides 19(7), 1241–1248 (1998). • Showed CST inhibits histamine release.
  Medline CASGoogle Scholar
• 40 Kruuger PG, Mahata SK, Helle KB. Catestatin (chromogranin A344–358) stimulates release of histamine from rat pleural and peritoneal mast cells. Ann. N. Y. Acad. Sci. 971, 349–351 (2002).
  MedlineGoogle Scholar
• 41 Kruger PG, Mahata SK, Helle KB. Catestatin (CgA344–364) stimulates rat mast cell release of histamine in a manner comparable to mastoparan and other cationic charged neuropeptides. Regul. Pept. 114(1), 29–35 (2003).
  Medline CASGoogle Scholar
• 42 Mazza R, Gattuso A, Mannarino C et al. Catestatin (chromogranin A344–364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart. Am. J. Physiol. Heart Circ. Physiol. 295(1), 9 (2008).
  Google Scholar
• 43 Bassino E, Fornero S, Gallo MP et al. A novel catestatin-induced antiadrenergic mechanism triggered by the endothelial PI3K–eNOS pathway in the myocardium. Cardiovasc. Res. 91(4), 617–624 (2011). • Provides evidence that CST inhibit inotropism and lusitropism through PI3K-eNOS pathway.
  Medline CASGoogle Scholar
• 44 Angelone T, Quintieri AM, Pasqua T et al. Phosphodiesterase type-2 and NO-dependent S-nitrosylation mediate the cardioinhibition of the antihypertensive catestatin. Am. J. Physiol. Heart Circ. Physiol. 302(2), 4 (2012).
  Google Scholar
• 45 Mazza R, Pasqua T, Gattuso A. Cardiac heterometric response: the interplay between catestatin and nitric oxide deciphered by the frog heart. Nitric Oxide 27(1), 40–49 (2012).
  Medline CASGoogle Scholar
• 46 Rao F, Wen G, Gayen JR et al. Catecholamine release-inhibitory peptide catestatin (chromogranin A(352–372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation 115(17), 2271–2281 (2007).
  Medline CASGoogle Scholar
• 47 Penna C, Alloatti G, Gallo MP et al. Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart. Cell. Mol. Neurobiol. 30(8), 1171–1179 (2010).
  Medline CASGoogle Scholar
• 48 Perrelli MG, Tullio F, Angotti C et al. Catestatin reduces myocardial ischaemia/reperfusion injury: involvement of PI3K/Akt, PKCs, mitochondrial KATP channels and ROS signalling. Pflugers Arch. 465(7), 1031–1040 (2013).
  Medline CASGoogle Scholar
• 49 Brar BK, Helgeland E, Mahata SK et al. Human catestatin peptides differentially regulate infarct size in the ischemic-reperfused rat heart. Regul. Pept. 165(1), 63–70 (2010).
  Medline CASGoogle Scholar
• 50 Theurl M, Schgoer W, Albrecht K et al. The neuropeptide catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor-dependent mechanism. Circ. Res. 107(11), 1326–1335 (2010). • Offers mechanisms for CST causing angiogenesis.
  Medline CASGoogle Scholar
• 51 Fornero S, Bassino E, Ramella R et al. Obligatory role for endothelial heparan sulphate proteoglycans and caveolae internalization in catestatin-dependent eNOS activation. BioMed. Res. Int. 2014, 783623 (2014).
  MedlineGoogle Scholar
• 52 Guo X, Zhou C, Sun N. The neuropeptide catestatin promotes vascular smooth muscle cell proliferation through the Ca²⁺-calcineurin-NFAT signaling pathway. Biochem. Biophys. Res. Commun. 407(4), 807–812 (2011).
  Medline CASGoogle Scholar
• 53 Zhang Z, Chen L, Zhong J, Gao P, Oudit GY. ACE2/Ang-(1–7) signaling and vascular remodeling. Sci. China Life Sci. 57(8), 802–808 (2014).
  Medline CASGoogle Scholar
• 54 Durakoglugil ME, Ayaz T, Kocaman SA et al. The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol. Anatol. J. Cardiol. 15(7), 577–585 (2015).
  Medline CASGoogle Scholar
• 55 Meng L, Wang J, Ding WH et al. Plasma catestatin level in patients with acute myocardial infarction and its correlation with ventricular remodelling. Postgrad. Med. J. 89(1050), 193–196 (2013).
  MedlineGoogle Scholar
• 56 Zhu D, Xie H, Wang X, Liang Y, Yu H, Gao W. Correlation of plasma catestatin level and the prognosis of patients with acute myocardial infarction. PLoS ONE 10(4), e0122993 (2015). • Follows up AMI patients and validated the correlation between plasma catestatin level and prognosis of AMI patients.
  MedlineGoogle Scholar
• 57 Liu L, Ding W, Zhao F, Shi L, Pang Y, Tang C. Plasma levels and potential roles of catestatin in patients with coronary heart disease. Scand. Cardiovasc. J. 47(4), 217–224 (2013).
  Medline CASGoogle Scholar
• 58 Pei Z, Ma D, Ji L et al. Usefulness of catestatin to predict malignant arrhythmia in patients with acute myocardial infarction. Peptides 55, 131–135 (2014).
  Medline CASGoogle Scholar
• 59 Lei J. Prognostic value of circulating catestatin levels for in-hospital heart failure in patients with acute myocardial infarction. Chin. J. Cardiol. 40(11), 914–919 (2012).
  Google Scholar
• 60 Liu R, Sun NL, Yang SN, Guo JQ. Catestatin could ameliorate proliferating changes of target organs in spontaneously hypertensive rats. Chin. Med. J. 126(11), 2157–2162 (2013).
  Medline CASGoogle Scholar
• 61 Fung MM, Salem RM, Mehtani P et al. Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin. Exp. Hypertens. 32(5), 278–287 (2010).
  Medline CASGoogle Scholar